Literature DB >> 33277615

Upregulated lncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10 axis.

Xiaoming Liu1, Dandan Peng2, Yixin Cao3, Yuanzhe Zhu3, Jianjun Yin4, Guangxing Zhang5, Xiaodong Peng6, Yanqiu Meng7.   

Abstract

Recent studies have illustrated the role of aberrant regulatory interactions in the mediation of malignant phenotypes of cancer cells, which could potentially provide novel therapeutic targets to limit the destructive recurrence and metastasis of hepatocellular carcinoma (HCC). Herein, we clarify the oncogenic role of the long noncoding RNA (lncRNA) distal-less homeobox 6 antisense 1 (DLX6-AS1) in HCC in vivo and in vitro. To this end, we knocked down lncRNA DLX6-AS1 and manipulated the expression of miR-513c to characterize their effects in HCC cell viability, migration, invasion, and apoptosis. Furthermore, we probed the interactions with miR-513c's target gene Cullin4A (Cul4A) and the degradation of Annexin A10 (ANXA10) protein. Our data show that lncRNA DLX6-AS1 and Cul4A were highly expressed, while miR-513c and ANXA10 were poorly expressed in HCC tissues and cells. Moreover, the silencing of lncRNA DLX6-AS1 impeded the viability, invasion, and migration of HCC cells, while stimulating cell apoptosis. Further data indicated that lncRNA DLX6-AS1 targeted and repressed miR-513c expression, where the tumor-inhibiting effects of lncRNA DLX6-AS1 silencing was achieved by elevating miR-513c expression. Importantly, the lncRNA DLX6-AS1 upregulated the expression of Cul4A through sponging of miR-513c. The silencing of Cul4A restricted the malignant phenotypes of HCC cells by repressing the ubiquitination-mediated degradation of ANXA10. In vivo experiments verified that lncRNA DLX6-AS1 promoted the progression of HCC through the miR-513c/Cul4A/ANXA10 axis. Thus, the silencing of lncRNA DLX6-AS1 impaired miR-513c-dependent Cul4A inhibition and subsequently elevated ubiquitination-mediated degradation of ANXA10, thereby preventing the occurrence and development of HCC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33277615     DOI: 10.1038/s41417-020-00233-0

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  2 in total

1.  Long noncoding RNA DLX6-AS1 targets miR-124-3p/CDK4 to accelerate Ewing's sarcoma.

Authors:  Xiaomei Lei; Siping Yang; Yuanyuan Yang; Juan Zhang; Yue Wang; Minhui Cao
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

2.  The mRNA, miRNA and lncRNA networks in hepatocellular carcinoma: An integrative transcriptomic analysis from Gene Expression Omnibus.

Authors:  Jian-Hua Xu; Wei-Hua Chang; Hang-Wei Fu; Tao Yuan; Ping Chen
Journal:  Mol Med Rep       Date:  2018-03-07       Impact factor: 2.952

  2 in total
  11 in total

Review 1.  Strategies of LncRNA DLX6-AS1 on Study and Therapeutics.

Authors:  Yanyan Zhao; Pei Li
Journal:  Front Genet       Date:  2022-06-01       Impact factor: 4.772

Review 2.  Research progress of DLX6-AS1 in human cancers.

Authors:  Yalan Luo; Peng Ge; Mengfei Wang; Haiyang Chen; Jiayue Liu; Tianfu Wei; Yuankuan Jiang; Jialin Qu; Hailong Chen
Journal:  Hum Cell       Date:  2021-09-11       Impact factor: 4.374

Review 3.  Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma.

Authors:  Zhixia Zhou; Zhan Wang; Jie Gao; Zhijuan Lin; Yin Wang; Peipei Shan; Mengkun Li; Tingting Zhou; Peifeng Li
Journal:  Mol Ther Oncolytics       Date:  2022-03-16       Impact factor: 6.311

4.  TNRC6C-AS1 Promotes Thyroid Cancer Progression by Upregulating LPAR5 via miR-513c-5p.

Authors:  Chuanming Tong; Chuan Wang; Yajie Wang; Xiongsheng Xiao
Journal:  Cancer Manag Res       Date:  2021-08-06       Impact factor: 3.989

5.  Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway.

Authors:  Jiewei Lin; Shuyu Zhai; Siyi Zou; Zhiwei Xu; Jun Zhang; Lingxi Jiang; Xiaxing Deng; Hao Chen; Chenghong Peng; Jiaqiang Zhang; Baiyong Shen
Journal:  J Exp Clin Cancer Res       Date:  2021-10-11

Review 6.  DLX6-AS1: A Long Non-coding RNA With Oncogenic Features.

Authors:  Soudeh Ghafouri-Fard; Sajad Najafi; Bashdar Mahmud Hussen; Aryan R Ganjo; Mohammad Taheri; Mohammad Samadian
Journal:  Front Cell Dev Biol       Date:  2022-02-25

7.  MILNP: Plant lncRNA-miRNA Interaction Prediction Based on Improved Linear Neighborhood Similarity and Label Propagation.

Authors:  Lijun Cai; Mingyu Gao; Xuanbai Ren; Xiangzheng Fu; Junlin Xu; Peng Wang; Yifan Chen
Journal:  Front Plant Sci       Date:  2022-03-25       Impact factor: 5.753

8.  Long noncoding RNA CERS6-AS1 modulates glucose metabolism and tumor progression in hepatocellular carcinoma by promoting the MDM2/p53 signaling pathway.

Authors:  Bo Xu; Yonggang Wei; Fei Liu; Lian Li; Siqi Zhou; Yufu Peng; Bo Li
Journal:  Cell Death Discov       Date:  2022-08-04

9.  Characterization of chromatin regulators identified prognosis and heterogeneity in hepatocellular carcinoma.

Authors:  Yin-Wei Dai; Han-Bin Chen; Ya-Ting Pan; Lin-Xi Lv; Wei-Ming Wang; Xiao-Hu Chen; Xiang Zhou
Journal:  Front Oncol       Date:  2022-09-09       Impact factor: 5.738

10.  lncRNA MT1JP-overexpression abolishes the silencing of PTEN by miR-32 in hepatocellular carcinoma.

Authors:  Shuhua Zhang; Jianqun Xu; Qing Chen; Fan Zhang; Hongjuan Wang; Hongrong Guo
Journal:  Oncol Lett       Date:  2021-06-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.